Pink Sheet Trades $1 million to $10 million in Daily Volume
Life Sciences Sector to Sizzle in 2009

Advanced Cell Technology, Inc. (OTC/Pink Sheets: ACTC) recently announced (Jan. 23, ’09) that it has accelerated its efforts to file an IND for its retinal pigment epithelium (RPE) cells program for the treatment of diseases of the eye in light of the decision by the FDA to grant clearance for a stem cell company to begin trials for the world's first study of a human embryonic stem cell-based therapy for people. The Company is close to securing the necessary funding which would allow it to make the requisite filings during the summer of this year. An IND filing is required in order to commence clinical trials in humans.

“We believe the recent administration change has increased funding opportunities for technologies such as ours,” said William M. Caldwell, CEO and Chairman of ACTC. “Today's decision to allow the world's first study of a human embryonic stem cell-based therapy for people perhaps reflects a new view towards stem cell-based therapies on the part of the FDA and government.”

Advanced Cell Technology is currently focused on using its proprietary technologies to generate stable cell lines including retinal pigment epithelium (RPE) cells for the treatment of diseases of the eye, including macular degeneration, which represents a $28 billion dollar market. Age-related macular degeneration (AMD) affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 years of age in the United States. AMD is a disorder that affects the macula of the eye that causes decreased visual acuity and possible loss of central vision. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 years of age have the condition.

The Company was featured on ABC Television’s special report titled, “Live to 150, Can You Do It? Secrets to Living Longer,” hosted by Barbara Walters on April 1, 2008.

Although ACTC was up 1,000% ($0.03 to $0.29) since December, we believe their current market cap of $19.5 million still represents a fraction of their potential value (see 3 year chart).
Stayed tuned for another aggressive Life Science selection coming soon before it doubles or triples or...

Click for Advanced Cell Technology Quote

Another idea to appreciate from…

As always, do your own due diligence to invest with confidence.

the OTC Money Group